Cover Image
市場調查報告書

Mersana Therapeutics, Inc. : 產品平台分析

Mersana Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226267
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Mersana Therapeutics, Inc. : 產品平台分析 Mersana Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 35 Pages
簡介

Mersana Therapeutics, Inc.(原Nanopharma Corp)是開發可將抗癌劑效力直接遞送到癌細胞之免疫偶聯物之製藥公司。總公司在美國麻薩諸塞州劍橋。

本報告提供Mersana Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估及暫停中的計劃等相關資訊。

Mersana Therapeutics, Inc.的基本資料

  • Mersana Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Mersana Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Mersana Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Mersana Therapeutics, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Mersana Therapeutics, Inc.:藥物簡介

Mersana Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Mersana Therapeutics, Inc.:最近的開發平台趨勢

Mersana Therapeutics, Inc.:暫停中的計劃

Mersana Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07647CDB

Summary

Global Markets Direct's, 'Mersana Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Mersana Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mersana Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mersana Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mersana Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mersana Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Mersana Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mersana Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mersana Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mersana Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mersana Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mersana Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mersana Therapeutics, Inc. Snapshot
    • Mersana Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Mersana Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Mersana Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Mersana Therapeutics, Inc. - Pipeline Products Glance
    • Mersana Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Mersana Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Mersana Therapeutics, Inc. - Drug Profiles
    • XMT-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XMT-1107
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XMT-1522
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mersana Therapeutics, Inc. - Pipeline Analysis
    • Mersana Therapeutics, Inc. - Pipeline Products by Target
    • Mersana Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Mersana Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Mersana Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Mersana Therapeutics, Inc. - Recent Pipeline Updates
  • Mersana Therapeutics, Inc. - Dormant Projects
  • Mersana Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mersana Therapeutics, Inc., Key Information
  • Mersana Therapeutics, Inc., Key Facts
  • Mersana Therapeutics, Inc. - Pipeline by Indication, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Mersana Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Mersana Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Mersana Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Mersana Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015
  • Mersana Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Mersana Therapeutics, Inc. - Phase I, 2015
  • Mersana Therapeutics, Inc. - Preclinical, 2015
  • Mersana Therapeutics, Inc. - Discovery, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Target, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Mersana Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Mersana Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Mersana Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Mersana Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Mersana Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Mersana Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Mersana Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top